Table 2. Effect of IL28B polymorphisms on the outcomes of HCV infection.

	Healthy controls	Subjects with persistence	Subjects with spontaneous clearance	Subjects with persistence vs. Subjects with spontaneous clearance	OR (95% CI)	P-value¥
rs12979860	n = 276	n = 464	n = 136
C allele	0.680±0.03	0.552±0.026	0.779±0.040	C vs T	2.87 (1.84–4.48)	0.00001
T allele	0.320±0.03	0.448±0.026	0.221±0.040
	n = 138	n = 232	n = 68
C/C	64 (46.4%)	89 (38.4%)	45 (66.2%)	C/C vs T/T	4.69 (1.99–11.07	0.0017
C/T	59 (42.7%)	78 (33.6%)	16 (23.5%)	C/C vs C/T	2.46 (1.29–4.70)	0.0543
T/T	15 (10.9%)	65 (28%)	7 (10.3%)	C/C vs C/T and T/T	3.14 (1.78–5.55	0.0004
rs8099917	n = 276	n = 464	n = 136
T allele	0.902±0.017	0.832±0.017	0.956±0.017	T vs G	4.38 (1.86–10.28)	0.0025
G allele	0.098±0.017	0.168±0.017	0.044±0.017
	n = 138	n = 232	n = 68
T/T	111 (80.4%)	158 (68.1%)	62 (91.2%)	T/T vs T/G	4.58 (1.89–11.08)	0.0029
T/G	27 (19.6%)	70 (30.2%)	6 (8.8%)	T/T vs G/G	3.55 (0.19–66.89)	0.2110
G/G	0 (0%)	4 (1.7%)	0 (0%)	T/T vs T/G and G/G	4.84 (2.00–11.69)	0.0017

^¥Bonferroni correction was applied.